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ABSTRACT
Objective: To study the clinico-microbiological profile of oral candidiasis in head and neck squamous cell cancer (HNSCC) patients undergoing 
curative radiotherapy (cRT).
Methods: Patients undergoing cRT and developing oral candidiasis were enrolled. Clinical features such as pain and xerostomia were recorded. 
Candida isolates from lesions were speciated using CHROMagar (Himedia Inc.), and antifungal susceptibility was determined using microbroth 
dilution (MBD). Patients were followed up to study the clinical course of infection.
Results: Of the 100 patients undergoing cRT, 79 developed oral candidiasis. Median duration to development of infection was 4 weeks (range: 
1-6.5 weeks). Mucositis was observed in 76 (96.2%) and xerostomia in 53 (67.1%) patients; 61 patients (77.2%) had symptoms attributable to 
candidiasis. However, there was no correlation between severity of infection and mucositis (p=0.84) or xerostomia (p=0.51). Candida albicans was the 
most frequent (47 patients, 59.4%) isolate, followed by Candida tropicalis (23 patients; 29.1%). All isolates were sensitive to nystatin, but fluconazole 
resistance/dose-dependent susceptibility was noted in 26 (32.9%) isolates. Both Candida krusei and two of four Candida glabrata isolate exhibited 
fluconazole resistance. All patients received treatment for Candidiasis. On follow-up, 1 month after cRT, oral candidiasis resolved with gradual 
recovery of mucositis in all patients.
Conclusion: Candida albicans was the most common cause of oral Candidiasis in HNSCC cRT, and all isolates were susceptible to nystatin in-vitro. 
All lesions resolved with recovery from mucositis. In addition, as no patient developed systemic candidiasis, it appears that oral candidiasis though 
troublesome is curable with treatment.
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INTRODUCTION
Candida species form a part of normal oral flora. Candida colonization 
rates of nearly 18% have been reported in healthy individuals [1]. 
However, various specific and non-specific defense mechanisms prevent 
the development of oral candidiasis. Colonization occurs whenever 
there is an imbalance in multiplication and clearance of Candida 
cells. This colonization can progress to infection whenever there is 
mucosal injury [1]. Mucositis and xerostomia are the most common 
complications of curative radiation therapy (cRT) for head and neck 
squamous cell carcinomas (HNSCC) and act in synergy to considerably 
increase the patient’s risk of developing oropharyngeal candidiasis. The 
incidence rates of oral candidiasis in these patients have been reported 
to be as high as 77% [2].
While there are several studies that have reported on changes in 
candidial colonization during the course of cRT, few have studied the 
clinical course of overt infection and its response to treatment. In 
this study, we attempted to understand the microbiological profile of 
oropharyngeal candidiasis in patients undergoing cRT for HNSCC in our 
hospital and study their susceptibility patterns.
METHODS
This was a prospective study which included 100 patients who received 
cRT for HNSCC and developing oropharyngeal candidiasis. Ethical 
clearance was obtained from the Institutional Ethical Committee. 
The study group included both patients undergoing primary RT 
(with or without chemotherapy) and adjuvant RT following definitive 
surgery. Patients receiving palliative RT, suffering from oropharyngeal 
candidiasis prior to start of treatment, and/or those with Grade IV 
trismus were excluded from the study. Informed consent was obtained 
from all patients for participating in the study. None of the patients 
received prophylactic topical or systemic antifungal treatment. 
Patients were monitored on a weekly basis for the development of 
oral candidiasis. Personal and clinical details were obtained from 
all the patients with suspected candidiasis. The site, size, extent, and 
morphological patterns of the Candida lesions were recorded. The 
severity of acute mucositis and xerostomia secondary to RT was noted 
and graded according to Common Terminology Criteria for Adverse 
Events grading system (version 4.0) [3] for all patients. Oral swabs 
collected from the suspected lesions were subjected to Gram-stain and 
culture on Sabouraud dextrose agar. Plates were observed after 24 hrs 
of incubation at 37°C. Candida colonies grown were speciated using 
CHROMagar (HiMedia Inc.). The plates with no growth were further 
incubated at examined after 48 hrs. Conventional tests such as Dalmau 
plate technique and germ tube test were also performed for speciation. 
Mircobroth dilution (MBD) test was performed for determining anti-
fungal susceptibility using Clinical and Laboratory Standards Institute 
(CLSI) M27-A2 reference standard [4]. Fluconazole and nystatin drug 
powders were obtained from Sigma-Aldrich.
Interpretation of MBD was done by appreciating the visible growth in 
each well. Growth was scored as per the scoring given in the reference 
standard guideline – Optically clear tube was graded as zero, slightly 
hazy growth as one, prominent decrease in turbidity as two, slight 
reduction in turbidity as three, and no reduction in turbidity as four.
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For fluconazole, lowest concentration at which score 2 was observed 
was considered as the minimum inhibitory concentration (MIC), 
whereas lowest concentration at which score 0 was observed was 
identified as MIC for nystatin. MIC value of <8 µg/ml was considered as 
susceptible, >32 µg/ml was considered resistant, and the isolates which 
had a MIC of 16-32 µg/ml were noted as susceptible dose dependent for 
fluconazole. There are no interpretive breakpoints available for nystatin 
by CLSI. In this study, the methodology described for amphotericin B by 
CLSI has been used to carry out MIC determination for nystatin. Patients 
were followed up for their response to therapy and until 1 month after 
completion of treatment to check any persistence of oral candidiasis.
RESULTS
Of the 100 patients who underwent definitive or adjuvant RT during the 
study period, 79 patients developed clinical evidence of candidiasis that 
was confirmed by culture. The mean age of the patients was 55 years 
(range: 29-86 years). General and clinical characteristics of the study 
population are described in Table 1.
The time of onset of oral candidiasis during RT was variable, with a 
median duration for developing the infection being 4 weeks since the 
start of RT (range: 1-6.5 weeks). The average radiation dose received 
at the time of developing candidiasis was 41.2 Gy (range: 14 Gy-66 Gy). 
The clinical characteristics of Candida infection are summarized 
in Table 2. Majority (77%) had symptoms secondary to mucositis, 
xerostomia, and/or candidiasis at the time of detection of infection. 
Pain on swallowing was the most common symptom (70%), followed 
by burning sensation in the mouth (34%), altered taste (18%), and 
nausea/vomiting (8%). On analyzing with one sample Chi-square test, 
patients with candidiasis were significantly likely to experience at least 
some pain (p=0.02), mucositis (p=0.001), and xerostomia (p=0.001).
Growth was scanty in 36 (45.6%), moderate in 24 (30.4%), and heavy 
in 19 (24%) samples. When the growth of Candida was evaluated in 
different grades of mucositis, it was seen that majority of positive 
cultures were obtained in Grade 1 and 2 mucositis. There was no 
statistical correlation between grades of mucositis and Candida 
growth (p=0.84). Even grades of trismus and xerostomia did not show 
any statistical correlation with degree of growth (p=0.79 and 0.51, 
respectively).
Speciation of the isolates revealed that Candida albicans were the 
most frequent (47 patients, 59.4%), followed by Candida tropicalis 
(23 patients; 29.1%). Other isolates included Candida glabrata (four 
patients), Candida krusei, and Candida parapsilosis (two patients each). 
One Candida famata was also identified.
All isolates were sensitive to nystatin by antifungal susceptibility 
testing. However, only 53 isolates were fluconazole susceptible. 
Fluconazole resistance was seen in 12 isolates and 14 exhibited dose-
dependent susceptibility (Table 3).
All patients who had microbiological evidence of candidiasis received 
treatment for oral candidiasis either in the form of topical or systemic 
antifungal therapy based on the clinical severity and grade of mucositis. 
Topical antifungal used was clotrimazole lozenges. Fluconazole was the 
preferred systemic agent and prescribed in 16 (89%) of the 18 patients 
receiving any systemic therapy. Two patients received itraconazole. 
All patients showed clinical resolution of oral candidiasis following 
1 month after completion of RT.
DISCUSSION
Oral candidiasis is a frequent complication of cRT for HNSCC, especially 
among oral cancers. This study was conducted to identify the burden 
and clinical features of oral candidiasis in these patients. The incidence 
of oral candidiasis during a typical 6-7 weeks course of cRT is quite 
high; 79% of our patients developed clinical evidence of oral candidiasis 
during the study period, which was confirmed by microbiological 
evidence in culture. The median time to onset of clinically evident 
candidiasis was 4 weeks in our study, and more than 70% of our patients 
had Grade II or higher oral mucositis at the time of development of 
infection. This reflects that the severity of mucositis increases with 
progress in RT which in turn increases the chances of development of 
oral candidiasis. Association of oral mucositis with the development 
of candidiasis is already established by some previous studies [5,6]. In 
one of such study of candidiasis among HNSCC patients, the incidence 
of oral thrush was much higher (55.2%) in patients who received RT 
to oral region as compared to the group which did not receive RT to 
oral region (11%) [5]. Similarly, in another study, candidiasis was 
associated with ≥ Grade II mucositis in 77% of the patients receiving 
RT for oral cancers [6]. However, we could not establish a significant 
relationship between grade of mucositis and severity of candidiasis. 
Similarly, there was no correlation between severity xerostomia 
and development of overt infection, even though xerostomia is a 
known risk factor for oral candidiasis. This is probably because most 
patients (67) had at least some degree of xerostomia at the time of 
developing infection. It has been reported that Candida colony forming 
unit counts were higher in patients with xerostomia when compared 
to patients with higher salivary flow rates [7]. In a patient with HNSCC 
receiving cRT, xerostomia and mucositis frequently coexist, making it 
difficult as to ascertain which toxicity is a greater predisposing factor. 
Coexistence of xerostomia and mucositis is highly likely to increase 
the risk of developing candidiasis; 55 of our patients with candidiasis 
had coexistent mucositis and xerostomia. It is also believed that overt 
candidiasis worsens the severity of acute radiation toxicity experienced 
by the patient, thus making the relationship between the toxicity of RT 
and oral candidiasis a vicious cycle. In a cohort study by Deng et al., 
Table 1: Demographic characteristics of the patients
Clinical parameter Variable N=100 (%)
Gender Males 79 (79)
Females 21 (21)














Grade of trismus ≤ I 87 (87)
II 7 (7)
III 6 (6)
Concurrent chemotherapy Administered 53 (53)
Not administered 47 (47)
Table 2: Patient related variables at the onset of Candida 
infection (N=79)
Clinical parameter Variable N (%) p value
Severity of pain 0 24 (30.3) 0.02
≤II 39 (49.4)
≥III 16 (20.3)
Grade of mucositis at 
onset of candidiasis
0 3 (3.8) 0.001
I-II 56 (70.9)
≥III 20 (25.3)
Grade of xerostomia at 
onset of candidiasis
0 26 (32.9) 0.001
I 47 (59.5)
II 6 (7.6)
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mouth soreness at the end of 4th week of RT was significantly higher in 
patients with Candida infection [5].
Many different techniques have been used by researchers to sample 
oral Candida lesion such as oral swab, oral rinse, and salivary sampling 
[8,9]. We used sterile swabs to collect sample from lesions as we aimed 
at speciating the Candida isolates from suspected lesion for which oral 
rinse or salivary samples may not be ideal. However, the latter sampling 
methods are effective in estimating the colonization rates of Candida. 
Shrestha et al. have quantitatively estimated the colonization of 
Candida in patients undergoing head and neck radiation using oral rinse 
method [10]. They reported a colonization rate of 100% for C. albicans 
followed by C. glabrata and C. tropicalis. C. albicans is by far the most 
common species isolated in many studies involving patients with head 
and neck radiotherapy [11,12]. Even in the present study, C. albicans 
was the most common isolate (59.4%). Among nonalbicans Candida 
(NAC), C. tropicalis was common (29.1) followed by C. parapsilosis, 
C. glabrata, and C. krusei. C. tropicalis is the common species among NAC 
group to cause bloodstream infections in patients with hematological 
malignancy [13]. The spectrum of Candida species isolated in patients 
undergoing head and neck radiotherapy by other studies is shown in 
Table 4.
Fluconazole resistance rates in Candida species are showing a steady 
increase. For instance, in a study on the antifungal susceptibility 
of C. tropicalis, fluconazole resistance was reported in 67% of 
isolates [16,17]. There are not many studies that have evaluated 
fluconazole resistance in Candida species isolated from HNSCC patients. 
Belazi et al. have reported a resistance rate of 34.7% in C. albicans, 
66.6% in C. glabrata, and 100% in C. krusei [6]. Our study has shown 
an overall resistance rate of 15.2% for fluconazole. The incidence of 
resistance was 10.7% in C. albicans, 13.7% in C. tropicalis, and 100% 
in C. krusei. This is expected as C. krusei is intrinsically resistant to 
fluconazole. Overall fluconazole resistance among NAC species was 
8.8% in our study. In general, azole resistance is seen more commonly 
in NAC species. Moreover, antifungal resistance is more seen in Candida 
species isolated from systemic candidiasis or in isolates producing 
biofilm [18].
All isolates were susceptible for nystatin. There are no interpretive 
breakpoints available for nystatin by CLSI. In this study, the methodology 
described for amphotericin-B by CLSI has been used to carry out 
MIC determination for nystatin. Nystatin resistance is generally less 
in Candida species as seen in other studies. The resistance rates are 
usually zero; however, there are reported resistance of 1-6% in some 
of the studies [19-21].
A major limitation of the present study was the lack of systematic 
analysis of the treatment response to oral candidiasis as treatment 
received by the patients ranged from topical agents to systemic 
antifungals. Moreover, a study design involving follow-up cultures 
would have helped in understanding the microbiological recovery in 
addition to clinical recovery.
CONCLUSION
Oral candidiasis is of major concern in patients on cRT for HNSCC as 
it enhances the side effects of RT. However, it is rare for these patients 
to develop systemic disease secondary to the oral lesion. Treatment 
of oral thrush is important for improving oral hygiene and potentially 
ameliorating symptoms to decrease the morbidity. Speciation and 
knowing the antifungal susceptibility will help in the accurate treatment 
of candidiasis in these cases.
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